AmorChem and Univalor Invest in IRCM Drug Discovery
Venture capital firm AmorChem and technology transfer and commercialization hub Univalor have made an undisclosed re-investment in a project led by Dr. Nabil Seidah of the Institut de recherches cliniques de Montréal (IRCM). The project, which was launched last year, is focused on drug discovery related to the treatment of hypercholesterolemia. AmorChem has since 2011 made seed-stage life sciences investments intended to help commercialize academic research carried out in Québec.
22 May 2013•5 mins read
